Images List Premium Download Classic

Obesity

Obesity-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Antibody therapy for modulating function of intestinal receptors and methods of treating diabetes and obesity
Circle 33 Llc
November 30, 2017 - N°20170342149

The present invention provides pharmaceutical compositions formulated for direct delivery to the gi tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the gi tract of the patient, compositions of the present invention wherein modulation of the ...
Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
Hanmi Science Co., Ltd
November 30, 2017 - N°20170342122

The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates ...
Glucagon/glp-1 agonists for the treatment of obesity
Medimmune Limited
November 30, 2017 - N°20170342121

This disclosure provides glp-1/glue agon agonist peptides for the treatment of metabolic diseases, e. G., obesity.
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Fumagillol heterocyclic compounds and methods of making and using same
Zafgen, Inc.
November 30, 2017 - N°20170342058

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
Fumigillol compounds and methods of making and using same
Zafgen, Inc.
November 30, 2017 - N°20170342043

The disclosure provides fumagillol type compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e. G. In the treatment of obesity are provided.
Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
Hanmi Science Co., Ltd
November 30, 2017 - N°20170340753

The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin fc of the present invention reduces food ...
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment for obesity
Sk Biopharmaceuticals Co., Ltd.
November 30, 2017 - N°20170340596

The present invention relates to a method for treating or preventing obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. The invention further relates to methods for reducing body weight and/or reducing food intake in a subject in need thereof, comprising administering to the subject a therapeutically effective ...
Anti-acth antibodies and use thereof
Alder Biopharmaceuticals, Inc.
November 23, 2017 - N°20170334987

The present invention is directed to antibodies and fragments thereof having binding specificity for acth. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the vh, vl and/or cdr polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-acth antibodies and binding fragments thereof conjugated ...
Thienopyranones as kinase and epigenetic inhibitors
Signalrx Pharmaceuticals, Inc.
November 23, 2017 - N°20170334925

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (...
New pyrazolopyrimidine derivatives as nik inhibitors
Janssen Pharmaceutical Nv
November 23, 2017 - N°20170334915

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to ...
New compounds as nik inhibitors
Janssen Pharmaceutica Nv
November 23, 2017 - N°20170334906

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to ...
New pyrazole derivatives as nik inhibitors
Janssen Pharmaceutica Nv
November 23, 2017 - N°20170334900

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to ...
Lkb1-ampk activators for therapeutic use in polycystic kidney disease
The University Of Kansas
November 23, 2017 - N°20170334892

Compounds are provided for use in treating polycystic kidney disease (pkd) and in associated methods that include a method of modulating (e. G., activating) liver kinase b1 (lkbi); and a method of modulating (e. G., decreasing activity) mammalian target of rapamycin (mtor). The methods may include introducing the compound in a therapeutically effective amount to a subject having pkd. The ...
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Neuromodulation device
Faculdade De CiÊncias MÉdicas Da Universidada Nova De Lisboa
November 23, 2017 - N°20170333708

The invention refers to a device for inhibiting the neural activity of a carotid sinus nerve (csn) or carotid body of a subject, the device comprising: one or more transducers configured to apply a signal to the csn or associated carotid body of the subject, optionally at least two such transducers; and a controller coupled to the one or more ...
A device for treating obesity and a corresponding delivery system
Faculdade De CiÊncias MÉdicas Da Universidada Nova De Lisboa
November 23, 2017 - N°20170333239

A device for the treatment of obesity, the device including an inflatable member positionable within the stomach of a patient and an elongated flexible sleeve positionable in the intestine of the patient and having a proximal end coupled to said inflatable member, a distal end and a side wall extending from said proximal end to said distal end and defining ...
Ovarian neuromodulation and associated systems and methods
Medtronic Ardian Luxembourg S.a.r.l.
November 23, 2017 - N°20170333126

Methods for treating polycystic ovary syndrome with therapeutic ovarian neuromodulation and associated systems and methods are disclosed herein. Polycystic ovary syndrome can be associated, for example, with a condition including at least one of oligo/amenorrhea, infertility, hirsutism, obesity, metabolic syndrome, insulin resistance, and increased cardiovascular risk profile. One aspect of the present technology is directed to methods that at ...
Organic compositions to treat beta-enac-related diseases
Arrowhead Pharmaceuticals, Inc.
November 16, 2017 - N°20170327829

The present disclosure relates to rnai agents useful in methods of treating beta-enac-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (pha1), liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a rnai agent to beta-enac.
Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center
November 16, 2017 - N°20170327827

The present invention is directed to constructs, compositions and methods for modulating platelet-type 12 lipoxygenase (12-lo) in adipose tissue in vivo. Specifically, the invention provides constructs encoding expression-inhibiting oligonucleic acids, e. G. Antisense and rna interfering (rnai) molecules, targeted to a platelet-type 12-lo gene or a transcript thereof, which are capable of reducing or silencing platelet-type 12-lo expression specifically in adipocytes ...
Omefibrates for treating dyslipidemia and cardiovascular disease
Jiva Pharma, Inc.
November 16, 2017 - N°20170327455

The present invention relates to the fibric acid derivatives of omega-3 fatty acids and their use in treating type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic syndrome, cancer, alzheimer's disease; and their use for modulating activity of peroxisome proliferator-activated receptors (ppars).
Treatment of diseases asssociated with fat accumulation
The Provost, Fellows, Foundation Scholars, & The Other Members Of The Board, Of The College Of The
November 16, 2017 - N°20170326208

The present invention is directed to immunmodulators in the form of compositions, compounds, proteins and/or fragments with rnase activity thereof for use in the treatment of diseases associated with fat accumulation, including obesity and obesity-related disorders and metabolic disorders.
Novel fat accumulation inhibitory peptide and pharmaceutical composition for preventing or treating obesity containing the ...
Nano Intelligent Biomedical Engineering Corporation Co., Ltd.
November 16, 2017 - N°20170326201

The disclosure relates to a fat accumulation inhibitory peptide which essentially comprises an amino acid sequence represented by seq id no: 1, a pharmaceutical composition for preventing or treating obesity, which contains the peptide, and a health functional food for preventing or alleviating obesity, which contains the peptide. The fat accumulation inhibitory peptide according to the present invention has the function ...
Loading